Related Experiment Video
Updated: Sep 20, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors
Claudia Piombino1, Laura Cortesi1
1Genetic Oncology Unit, Department of Oncology and Haematology, University Hospital of Modena, 41125 Modena, Italy.
Abstract:
PARP1 enzyme plays an important role in DNA damage recognition and signalling. PARP inhibitors are approved in breast, ovarian, pancreatic, and prostate cancers harbouring a pathogenic variant in BRCA1 or BRCA2, where PARP1 inhibition results mainly in synthetic lethality in cells with impaired homologous recombination. However, the increasingly wide use of PARP inhibitors in clinical practice has highlighted the problem of resistance to therapy. Several different mechanisms of resistance have been proposed, although only the acquisition of secondary mutations in BRCA1/2 has been clinically proved. The aim of this review is to outline the key molecular findings that could explain the development of primary or secondary resistance to PARP inhibitors, analysing the complex interactions between PARP1, cell cycle regulation, PI3K/AKT signalling, response to stress replication, homologous recombination, and other DNA damage repair pathways in the setting of BRCA1/2 mutated cancers.
Insights
PARP inhibitors are crucial for treating BRCA1/2-mutated cancers, but resistance is a growing concern. This review explores molecular mechanisms driving resistance to PARP inhibitors in these cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly (ADP-ribose) polymerase 1 (PARP1) is vital for DNA damage response.
- PARP inhibitors are effective in BRCA1/2-mutated cancers via synthetic lethality.
- Therapeutic resistance to PARP inhibitors is an emerging clinical challenge.
Purpose of the Study:
- To review molecular mechanisms underlying primary and secondary resistance to PARP inhibitors.
- To analyze interactions between PARP1, DNA repair, and signaling pathways in BRCA1/2-mutated cancers.
Main Methods:
- Literature review of molecular findings on PARP inhibitor resistance.
- Analysis of interactions between PARP1, cell cycle, PI3K/AKT signaling, and DNA repair pathways.
Main Results:
- Several resistance mechanisms have been proposed, with secondary BRCA1/2 mutations being clinically validated.
- Understanding complex interactions is key to elucidating resistance development.
Conclusions:
- Elucidating resistance mechanisms is critical for improving PARP inhibitor efficacy in BRCA1/2-mutated cancers.
- Further research into interconnected pathways is needed to overcome resistance.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
DNA Damage can Stall the Cell Cycle
Restarting Stalled Replication Forks
Long-patch Base Excision Repair
Abnormal Proliferation
Base Excision Repair
The first step of...

